Upcoming Medical Conferences in Missoula

The Goldfarb Foundation 2019 Montana Meeting is organized by The Goldfarb Foundation and will be held from Sep 04 - 08, 2019 at DoubleTree by Hilton Hotel Missoula - Edgewater, Missoula, Montana, United States of America. This CME Conference has been approved for a maximum of 12 CE contact hours. Additional details will be posted as soon as they are available.

Making the Connection - CME is organized by Taking Control of Your Diabetes (TCOYD) and will be held on Sep 07, 2019 at Hilton Garden Inn Missoula, Missoula, Montana, United States of America. Accreditation: AMA: The University of California, San Diego School of Medicine designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses: For the purposes of recertification, the American Nurses Credentialing Center accepts AMA PRA Cate­gory 1 Credits™ issued by organizations accredited by the ACCME. For the purpose of re-licensure, the Califor­nia Board of Registered Nursing accepts AMA PRA Category 1 credits™ (report up to 5.75 hours of credit and list “CME Category 1” as the provider number). Physician Assistants: The AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Phy­sician assistants may receive a maximum of 5.75 hours of Category 1 credit for completing this program. Certified Diabetes Educators: The University of California, San Diego is accredited by the ACCME, which is on the NCBDE list of approved providers. Credit Designation: Global Education Group designates this continuing education activity for 5.75 contact hour(s) (0.65 CEUs) of the Accreditation Council for Pharmacy Education. What You Will Learn: We focus on four distinct areas of the most cutting-edge diabetes management strategies: • Patient-provider relationships with a focus on communication methods to improve adherence and persistence. • Oral agents for the treatment of type 2 diabetes and their effect on cardiovascular health. • Injectable therapies, including insulin, for use in patients with type 2 diabetes. • New and emerging strategies for patients with type 1 diabetes. Learning Objectives At course completion, participants should be able to: • Identify the different pathophysiologic defects associated with type 2 diabetes and how all the pharmacologic agents (oral and injectable) address these specific abnormalities. Additional details will be posted as soon as they are available. • Review the recently published cardiovascular outcome trials (CVOTs) on oral and injectable type 2 medications. • Discuss the implications of recently published cardiovascular outcome trials (CVOTS) on oral and injectable type 2 medications. • Discuss approaches to combination therapy with the currently available oral agents, as well as physician and patient-directed insulin titration strategies and the basal-bolus approach. • Outline the most up-to-date clinical information on GLP-1 receptor agonists and SGLT-2 inhibitors. • Design a treatment plan for multiple daily injection regimens and insulin pump therapy. • Interpret continuous glucose monitoring data. • Select effective therapeutic adjustments based on trending or rate of change arrows, time in range, and standard deviation. • Evaluate the physical and emotional barriers that prevent patients with diabetes from being persistent and adherent to their therapeutic regimen(s). • Employ innovative and dynamic strategies for communication with patients to strengthen provider-patient relations and improve patient outcomes. Additional details will be posted as soon as they are available.